SURFACE ONCOLOGY INC (SURF)
US86877M2098 - Common Stock
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BG, SURF, KLR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURF
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SURF, RETA, INPX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
IMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Synergy Of Coherus And Surface Oncology: Analyst Forecasts $50M Savings And 2024 Profitability
Truist Securities analyst Robyn Karnauskas reiterated a Buy rating on the shares of Coherus BioSciences, Inc.
Moore Kuehn Encourages SURF, NEX, NETI, and DICE Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Shareholder Alert: Ademi LLP investigates whether Surface Oncology, Inc. has obtained a Fair Price in its transaction with Coherus
/PRNewswire/ -- Ademi LLP is investigating Surface (Nasdaq: SURF) for possible breaches of fiduciary duty and other violations of law in its transaction with...
SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders
Coherus to Acquire Surface Oncology
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023 Projected cash...
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –...
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
SRF388 clinical program advancing well; updated clinical data expected in the first half of 2023 First patient dosed in a Phase 1/2 study evaluating...
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation...